

genOway: strong growth of academic customer portfolio in the first semester of 2009

Besides its business dynamic towards biopharmaceutical companies, genOway is pursuing growth among its international academic customers

Lyon, France – September 2, 2009 - genOway (ALTERNEXT-NYSE Euronext: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today announced the strong growth of its academic partners portfolio during the first semester of 2009.

Over the first six-month period of the current fiscal year, the value of contracts with academic players increased by 27% to reach EUR 2.19 million versus 1.72 million in the previous year.

This increase in contracts with academic institutions has been particularly pronounced in the United States. In fact, during the first half of the year, genOway has, for example, consolidated its position as the major supplier of animal models for the University of Los Angeles (UCLA), Columbia (New York), Harvard (Boston) and Pittsburgh. In Europe, growth has also been sustained through contracts signed with, among others, the Universities of Cambridge, Frankfurt, Munich and Oxford.

The growth in the academic customers portfolio represents the second phase of growth for the Company, which reported, during the first semester of 2009, the strengthening of its biopharmaceutical customers portfolio. Moreover, negotiations are also ongoing in order to sign new contracts with major players in the biopharmaceutical industry in the second half of 2009.

It should be noted that the financial terms of the previously mentioned academic contracts are perfectly in line with the profitability objectives of the Company.

“The recurrent enlargement of our academic customers portfolio is a key feature of our corporate strategy because it complements the growth of our industrial customers portfolio. Academic laboratories are very interested in the innovations provided by our technologies and they represent important prescribers for the biopharmaceutical industry. Our technologies are perfectly suited to meet the demands of both types of customer. Furthermore, we anticipate continued strong growth due to investments made by different countries in public research, especially in the United States with President Obama’s Economic Stimulus Plan. The acquisition of these new clients supports our corporate strategy of combining growth and profitability” **said Alexander Fraichard, CEO of genOway.**

About genOway

genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology Company developing genetically modified and high value added research models for the bio-pharmaceutical, chemical, agrochemical and food industry as well as for academic research. With highly qualified scientific personnel, the Company has a work force of 60 people and operates in over 22 countries in Europe, Asia and North America, and supplies more than 250 customers. genOway is a leader in its market in terms of both size and customer portfolios. The Company's development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend towards outsourcing the production of genetically modified research models, genOway has signed many contracts with leaders of the pharmaceutical industry (Pfizer, Bayer, Boehringer Ingelheim, etc.), and with the most prestigious academic research centers (King's College and the University of Manchester in England, Duke University and the National Institutes of Health in the United States, the Institut Pasteur in France, NGFN and the Max Planck Institutes in Germany, etc.). To strengthen its technological position and benefit from worldwide business partners, genOway has signed strategic alliances with leading companies in their field: Charles River Laboratories (NYSE: CRL, a world leader in supplying laboratory animals), Invitrogen (NASDAQ: IVGN, world leader in supplying molecular biology reagents). For more information please consult www.genoway.com.

Press relations: Marie Norbert - genOway - norbert@genoway.com

Contact for investors: Alexandre Fraichard, CEO - genOway

Milestones - press & investors relations: Bruno Arabian / Jacques-Olivier Costa
Tel.: +33 (0)1 75 44 87 40 / 42 – E-mail: barabian@milestones.fr / jocosta@milestones.fr

Warning: This press release contains certain prospective statements, either express or implied, concerning genOway and its activities. These statements rely on certain risks, either known or unknown, uncertainties or other factors, that may lead to genOway's actual results, financial condition, performance or achievements differing significantly from the results, financial condition, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to updating the prospective statements contained therein, either as a result of new information, future events or any other occurrence. For a detailed description of the types of risks or uncertainties likely to cause a difference between genOway's actual results, financial condition, performance or achievements and those contained in the prospective statements, please refer to the section on "Risk Factors" in the prospectus available on the genOway website: www.genoway.com.